載入中
NASDAQHealthcareMedical - Instruments & Supplies
最新資料
US$2.06
+US$0.37 · +21.89%
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
收盤時
US$2.06
+US$0.37 · +21.89%
盤中時間採用ET。市場資料可能有所延遲。
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
日內區間
目前US$2.06
52週區間
目前US$2.06
盤中時間採用ET。市場資料可能有所延遲。
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
日內區間
目前US$2.06
52週區間
目前US$2.06
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（SGD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4.99萬 SGD | 4.83萬 SGD | 10.08萬 SGD | 5.66萬 SGD | 5.85萬 SGD |
| 銷貨成本 | 5.05萬 SGD | 5.13萬 SGD | 6.42萬 SGD | 3.66萬 SGD | 3.54萬 SGD |
| 毛利 | −645 SGD | −3024 SGD | 3.66萬 SGD | 2萬 SGD | 2.31萬 SGD |
| 研究與開發 | 22.69萬 SGD | 24.14萬 SGD | 16.77萬 SGD | 29.29萬 SGD | 27.98萬 SGD |
| 銷售、一般及管理費用 | 439.46萬 SGD | 126.93萬 SGD | 83.34萬 SGD | 83.04萬 SGD | 24.82萬 SGD |
| 營業費用 | 456.7萬 SGD | 164.22萬 SGD | 110.49萬 SGD | 119.58萬 SGD | 57.58萬 SGD |
| 利息收入 | 2.66萬 SGD | — | — | — | — |
| 利息支出 | 1.47萬 SGD | 3.72萬 SGD | 5.66萬 SGD | 2017 SGD | 2783 SGD |
| 折舊和攤銷 | 3.65萬 SGD | 4.22萬 SGD | 3.51萬 SGD | 2.91萬 SGD | 2.75萬 SGD |
| 營業利益 | −456.76萬 SGD | −164.53萬 SGD | −106.83萬 SGD | −117.58萬 SGD | −55.28萬 SGD |
| 淨利 | −467.34萬 SGD | −156.05萬 SGD | −111.96萬 SGD | −109.45萬 SGD | −51.97萬 SGD |
公司資料更新於 2026年10月13日。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
